Drug intelligence / Profile preview

obidoxime

Development stage
Unknown
Lead developer
Emergent BioSolutions
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Oral
01

Overview

Obidoxime is a small molecule drug belonging to the oxime family, primarily used as an antidote for organophosphate poisoning, including exposure to nerve agents (such as sarin, tabun, VX) and organophosphorus pesticides. Its main mechanism of action is reactivation of acetylcholinesterase (AChE) that has been inhibited by organophosphates. Obidoxime achieves this by having a higher affinity for the phosphate group bound to AChE than the enzyme itself; it removes the phosphate group from AChE, restoring its normal function and allowing elimination of the resulting compound via urine. It is considered more potent than pralidoxime in reactivating AChE inhibited by certain agents. Clinical use often involves combination with atropine to manage cholinergic crisis symptoms during poisoning events[1][2][5][6].

Brand names
obidoxime tablets
Other names
obidoximumobidoxim kationObidoxim [German]
02

Targets

AcetylcholinesteraseButyrylcholinesterase

Beyond the preview

Go deeper on obidoxime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on obidoxime.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call